-
Je něco špatně v tomto záznamu ?
Technical Note: Impact of cell repopulation and radionuclide uptake phase on cell survival
M. Šefl, I. Kyriakou, D. Emfietzoglou,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
PubMed
27277018
DOI
10.1118/1.4948504
Knihovny.cz E-zdroje
- MeSH
- analýza přežití MeSH
- antitumorózní látky farmakokinetika farmakologie MeSH
- biologické modely MeSH
- nádory farmakoterapie patofyziologie MeSH
- proliferace buněk účinky léků MeSH
- radiofarmaka farmakokinetika farmakologie MeSH
- radioizotopy fosforu farmakokinetika farmakologie MeSH
- radioizotopy jodu farmakokinetika farmakologie MeSH
- viabilita buněk účinky léků fyziologie MeSH
- vztah dávky záření a odpovědi MeSH
- yterbium farmakokinetika farmakologie MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To study theoretically the impact on cell survival of the radionuclide uptake rate inside tumor cells for a single administration of a radiopharmaceutical. METHODS: The instantaneous-uptake model of O'Donoghue ["The impact of tumor cell proliferation in radioimmunotherapy," Cancer 73, 974-980 (1994)] for a proliferating cell population irradiated by an exponentially decreasing dose-rate is here extended to allow for the monoexponential uptake of the radiopharmaceutical by the targeted cells. The time derivative of the survival curve is studied in detail deducing an expression for the minimum of the surviving fraction and the biologically effective dose (BED). RESULTS: Surviving fractions are calculated over a parameter range that is clinically relevant and broad enough to establish general trends. Specifically, results are presented for the therapy radionuclides Y-90, I-131, and P-32, assuming uptake half-times 1-24 h, extrapolated initial dose-rates 0.5-1 Gy h(-1), and a biological clearance half-life of seven days. Representative radiobiological parameters for radiosensitive and rapidly proliferating tumor cells are used, with cell doubling time equal to 2 days and α-coefficient equal to 0.3 and 0.5 Gy(-1). It is shown that neglecting the uptake phase of the radiopharmaceutical (i.e., assuming instantaneous-uptake) results in a sizeable over-estimation of cell-kill (i.e., under-estimation of cell survival) even for uptake half-times of only a few hours. The differences between the exponential-uptake model and the instantaneous-uptake model become larger for high peak dose-rates, slow uptakes, and (slightly) for long-lived radionuclides. Moreover, the sensitivity of the survival curve on the uptake model was found to be higher for the tumor cells with the larger α-coefficient. CONCLUSIONS: The exponential-uptake rate of the radiopharmaceutical inside targeted cells appears to have a considerable effect on the survival of a proliferating cell population and might need to be considered in radiobiological models of tumor cell-kill in radionuclide therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013789
- 003
- CZ-PrNML
- 005
- 20170418103351.0
- 007
- ta
- 008
- 170413s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1118/1.4948504 $2 doi
- 035 __
- $a (PubMed)27277018
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šefl, Martin $u Medical Physics Laboratory, Medical School, University of Ioannina, Ioannina 45110, Greece and Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague 11519, Czech Republic.
- 245 10
- $a Technical Note: Impact of cell repopulation and radionuclide uptake phase on cell survival / $c M. Šefl, I. Kyriakou, D. Emfietzoglou,
- 520 9_
- $a PURPOSE: To study theoretically the impact on cell survival of the radionuclide uptake rate inside tumor cells for a single administration of a radiopharmaceutical. METHODS: The instantaneous-uptake model of O'Donoghue ["The impact of tumor cell proliferation in radioimmunotherapy," Cancer 73, 974-980 (1994)] for a proliferating cell population irradiated by an exponentially decreasing dose-rate is here extended to allow for the monoexponential uptake of the radiopharmaceutical by the targeted cells. The time derivative of the survival curve is studied in detail deducing an expression for the minimum of the surviving fraction and the biologically effective dose (BED). RESULTS: Surviving fractions are calculated over a parameter range that is clinically relevant and broad enough to establish general trends. Specifically, results are presented for the therapy radionuclides Y-90, I-131, and P-32, assuming uptake half-times 1-24 h, extrapolated initial dose-rates 0.5-1 Gy h(-1), and a biological clearance half-life of seven days. Representative radiobiological parameters for radiosensitive and rapidly proliferating tumor cells are used, with cell doubling time equal to 2 days and α-coefficient equal to 0.3 and 0.5 Gy(-1). It is shown that neglecting the uptake phase of the radiopharmaceutical (i.e., assuming instantaneous-uptake) results in a sizeable over-estimation of cell-kill (i.e., under-estimation of cell survival) even for uptake half-times of only a few hours. The differences between the exponential-uptake model and the instantaneous-uptake model become larger for high peak dose-rates, slow uptakes, and (slightly) for long-lived radionuclides. Moreover, the sensitivity of the survival curve on the uptake model was found to be higher for the tumor cells with the larger α-coefficient. CONCLUSIONS: The exponential-uptake rate of the radiopharmaceutical inside targeted cells appears to have a considerable effect on the survival of a proliferating cell population and might need to be considered in radiobiological models of tumor cell-kill in radionuclide therapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antitumorózní látky $x farmakokinetika $x farmakologie $7 D000970
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $x fyziologie $7 D002470
- 650 _2
- $a vztah dávky záření a odpovědi $7 D004307
- 650 _2
- $a radioizotopy jodu $x farmakokinetika $x farmakologie $7 D007457
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a nádory $x farmakoterapie $x patofyziologie $7 D009369
- 650 _2
- $a radioizotopy fosforu $x farmakokinetika $x farmakologie $7 D010761
- 650 _2
- $a radiofarmaka $x farmakokinetika $x farmakologie $7 D019275
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a yterbium $x farmakokinetika $x farmakologie $7 D015018
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kyriakou, Ioanna $u Medical Physics Laboratory, Medical School, University of Ioannina, Ioannina 45110, Greece.
- 700 1_
- $a Emfietzoglou, Dimitris $u Medical Physics Laboratory, Medical School, University of Ioannina, Ioannina 45110, Greece.
- 773 0_
- $w MED00003245 $t Medical physics $x 2473-4209 $g Roč. 43, č. 6 (2016), s. 2715
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27277018 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170418103659 $b ABA008
- 999 __
- $a ok $b bmc $g 1200254 $s 974567
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 43 $c 6 $d 2715 $i 2473-4209 $m Medical physics $n Med Phys $x MED00003245
- LZP __
- $a Pubmed-20170413